antihemophilic

(redirected from antihaemophilic)

antihemophilic

 [an″te-, an″ti-he″mo-fil´ik]
1. effective against the bleeding tendency in hemophilia.
2. an agent that has this effect.

an·ti·he·mo·phil·ic

(an'tē-hē-mō-fil'ik)
Correcting or counteracting the hemorrhagic tendency in hemophilia.
Synonym(s): antihaemophilic.
[anti- + hemophilic]
References in periodicals archive ?
The product is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihaemophilic Factor when used to decrease the frequency of bleeding.
Cryoprecipitated CRYO Group to group Antihaemophilic Factor Cross-match to transfusion ratio was not calculated for FFP, RDP, SDP, CRYO as cross-matching was not done between the patient's blood and those components.
Effect of anti-hemophilic factor on one-stage clotting tests: a presumptive test for haemophilia and a simple one stage antihaemophilic factor assay procedure.
Further experience in use of Human Antihaemophilic Globulin (H.A.H.G.) for the control of bleeding after dental extraction in haemophilic patients: A report to the Medical Research Council's Working Party on Human Antihaeomophilic Globulin.
Most blood for transfusion is collected as whole blood (WB), or venous blood with an added preservative, and then separated by centrifugation into different components, such as red blood cells, plasma, cryoprecipitated antihaemophilic factor (AHF), and platelets.
List of biopharmaceuticals that have received approval from MOH as biosimilar Products Name of company 1 IFN alpha Pasteur Institute of Iran, Poyesh Daro 2 G-CSF Poyesh Daro 3 EPO alpha Pasteur Institute of Iran, Poyesh Daro, Notarkib 4 IFN beta 1a CinnaGen, (CinnoVex) 5 IFN beta 1a CinnaGen (ReciGen) 6 Epo beta CinnaGen, Zahravi 7 PTH CinnaGen 8 Buscerlin CinnaGen 9 Interferon beta 1b Zist daro Danesh 10 Interferon gamma NoTarkib 11 Peg-Interferon alpha Poyesh Daro 12 Antihaemophilic AryoGen factor VII 13 HBS (Vaccine) Pasteur Institute Table 3.
High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate.
Anti-idiotypic suppression of auto-antibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.
Novo Nordisk, a Danish pharmaceutical company, has launched its Novoeight (Antihaemophilic Factor [Recombinant]) in the United States, it was reported on Friday.